Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions

Malaria remains a persistent challenge in global health, disproportionately affecting populations in endemic regions (e.g., sub-Saharan Africa). Despite decades of international collaborative efforts, this parasitic disease continues to claim hundreds of thousands of lives each year, with young children and pregnant women enduring the heaviest burden of malaria. The introduction of pre-erythrocytic malaria vaccines (RTS,S/AS01 and R21/Matrix-M), represents an important milestone in malaria control efforts with promising results from the erythrocytic vaccine RH5.1/Matrix-M in recent clinical trials. However, the approval of these vaccines is accompanied by significant challenges such as the limited efficacy, the complexity of multi-dose regimens, and numerous barriers to widespread implementation in resource-limited settings. This concise review provides an overview of the historical development and current status of malaria vaccines, tracking their milestones from initial scientific breakthroughs to the deployment of first-generation vaccines. The review also examines the complex challenges to broad malaria vaccination coverage, including logistical barriers, healthcare infrastructure effect, financial limitations, malaria vaccine hesitancy, among other obstacles in malaria-endemic regions. Additionally, we explore promising developments in malaria vaccination, such as next-generation candidates (e.g., mRNA-based vaccines), that hold the potential to offer improved efficacy, longer-lasting protection, and greater scalability. Finally, we emphasize the critical need to integrate malaria vaccination efforts with established malaria control interventions (e.g., insecticide-treated bed nets, vector control strategies, and anti-malarial drugs). Based on this review, we concluded that achieving sustained control of malaria morbidity and mortality will require strong global collaboration, sufficient funding, and continuous efforts to address inequities in access and delivery of malaria control measures including the malaria vaccines.